Abstract

To observe and study the clinical efficacy of Bailing tablets combined with the method of strengthening the spleen, benefiting the kidney, removing turbidity and removing blood stasis in the treatment of patients with gouty nephropathy, and to provide a reliable theoretical basis and clinical basis. A total of 120 patients with primary gouty nephropathy diagnosed in our hospital from December 2018 to December 2020 were divided into intervention group and control group (randomized). The control group was treated with Bailing tablets alone, while the intervention group was treated with Bailing tablets combined with the method of strengthening the spleen, benefiting the kidney, removing turbidity and removing blood stasis. Clinical efficacy, syndrome efficacy, renal function, urine protein, immune status, psychological status, etc., were compared between the two groups after treatment. The intervention group significantly improved the clinical overall response rate (93.3 % vs. 81.6 %, p<0.05), with a post-treatment creatinine of (127.1±23.1) μmol/l in the intervention group compared to (140.3±37.3) μmol/l in the control group (p<0.05). The cluster of differentiation 4/cluster of differentiation 8 in the treatment group was (1.23±0.17), which was significantly lower than that (1.89±0.18) in the control group (p<0.05). Adverse effects were generally similar between the two groups (p>0.05). The treatment of gouty nephropathy using Bailing tablets combined with the method of strengthening the spleen, benefiting the kidney, removing turbidity and removing blood stasis is clinically important for improving renal function, reducing the occurrence of adverse effects and improving systemic immunity, and is a safe and effective drug for the treatment of gouty nephropathy.